Metabolismo De Lipideos !new! 【PREMIUM • REVIEW】
Lipids, broadly defined as hydrophobic or amphipathic biological molecules, are far more than mere passive energy reserves. The term "metabolismo de lípidos" encompasses a complex, highly regulated network of catabolic and anabolic pathways that are fundamental to cellular life. These pathways govern the breakdown of dietary fats for energy (β-oxidation), the synthesis of fatty acids and complex lipids (lipogenesis), and the formation and clearance of lipoproteins for transport. Disruptions in lipid metabolism are central to the pathogenesis of prevalent metabolic diseases, including obesity, atherosclerosis, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). This essay will provide a detailed examination of the core pathways of lipid metabolism—digestion and absorption, transport, catabolism (β-oxidation and ketogenesis), and anabolism (lipogenesis and lipogenesis)—highlighting their biochemical mechanisms, regulatory logic, and physiological integration.
Introduction
Lipid metabolism is exquisitely controlled by hormonal and nutritional signals. Insulin promotes anabolism (lipogenesis, TAG storage) and suppresses catabolism (inhibits HSL, activates ACC). Glucagon and epinephrine do the opposite, activating lipolysis and β-oxidation. The AMPK (AMP-activated protein kinase) system acts as a cellular fuel gauge: low energy (high AMP) activates AMPK, which shuts down energy-consuming anabolic pathways (e.g., ACC, HMG-CoA reductase) and turns on catabolic ones (e.g., fatty acid uptake and oxidation). metabolismo de lipideos
The journey of dietary lipids begins in the gastrointestinal tract. The hydrophobic nature of triglycerides (TAGs), phospholipids, and cholesterol esters necessitates emulsification by bile salts in the small intestine. Pancreatic lipase, along with its cofactor colipase, then cleaves TAGs into free fatty acids (FFAs) and 2-monoacylglycerols. Phospholipase A2 acts on phospholipids, while cholesterol esterase hydrolyzes cholesterol esters. These breakdown products are incorporated into mixed micelles, which diffuse to the enterocyte brush border for absorption. Disruptions in lipid metabolism are central to the
Once inside the mitochondrial matrix, β-oxidation proceeds as a four-step cycle (dehydrogenation, hydration, dehydrogenation, thiolysis) that shortens the fatty acid chain by two carbons (acetyl-CoA) per turn. For a saturated 16-carbon palmitate, this yields 8 acetyl-CoA, 7 FADH2, and 7 NADH. The acetyl-CoA enters the TCA cycle for complete oxidation to CO2 and water, generating substantial ATP via oxidative phosphorylation. In times of prolonged fasting or uncontrolled diabetes, however, the liver produces acetyl-CoA in excess of the TCA cycle’s capacity. This surplus is channeled into —the synthesis of ketone bodies (acetoacetate, β-hydroxybutyrate, and acetone). Ketone bodies serve as a water-soluble, alternative fuel for the brain, heart, and muscle, preserving glucose for obligate users like red blood cells. Pathological overproduction leads to ketoacidosis, a life-threatening condition. Inside the cell
Inside the enterocyte, FFAs and monoacylglycerols are rapidly re-esterified to form TAGs. These, along with newly synthesized cholesteryl esters and phospholipids, are packaged into chylomicrons—the largest and least dense lipoproteins. Chylomicrons enter the lymphatic system (lacteals) and then the bloodstream, delivering dietary lipids to peripheral tissues, particularly adipose tissue and muscle. At the capillary endothelium of these tissues, lipoprotein lipase (LPL) hydrolyzes chylomicron TAGs, releasing FFAs for uptake (storage in adipocytes or oxidation in muscle). The resulting chylomicron remnants, depleted of TAGs, are cleared by the liver via receptor-mediated endocytosis. This hepatic-centric process sets the stage for endogenous lipid metabolism, where the liver produces very-low-density lipoproteins (VLDL) to distribute TAGs synthesized de novo to extrahepatic tissues.
Inside the cell, FFAs are activated to fatty acyl-CoA by acyl-CoA synthetase. The critical entry step into the mitochondria, where β-oxidation occurs, is mediated by the carnitine shuttle. The enzyme carnitine palmitoyltransferase I (CPT1) is the rate-limiting, regulated step; it converts fatty acyl-CoA to acylcarnitine, which is transported across the inner mitochondrial membrane by translocase and then reconverted to acyl-CoA by CPT2. Malonyl-CoA, the first intermediate in fatty acid synthesis, allosterically inhibits CPT1—a prime example of reciprocal regulation between catabolism and anabolism.